Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Effects of dapagliflozin on serum and urinary uric acid levels in patients with type 2 diabetes: a prospective pilot trial

Fig. 1

Clinical trial flow chart. T2DM, type 2 diabetes mellitus; NGT, normal glucose tolerance; BMI, body mass index; HbA1c, glycated hemoglobin; SUA, serum uric acid; TC, total cholesterol; TG, triglyceride; LDL-c, low-density lipoprotein cholesterol; HDL-c, high-density lipoprotein cholesterol; UUA, urinary uric acid; UNa, urinary sodium; UCl, urinary chloride; FEUA, fractional excretion of uric acid; FENa, fractional excretion of sodium; FECl, fractional excretion of chloride; OGTT, oral glucose tolerance test; AUCGlu, area under the curve of glucose; AUCIns, area under the curve of insulin; HOMA-IR, homeostasis model assessment of insulin resistance; HOMA-β, homeostasis model assessment of β-cell function; QUICKI, quantitative insulin sensitivity check index; ISIstumvoll, insulin sensitivity index proposed by Stumvoll et al.; ISIMatsuda, insulin sensitivity index proposed by Matsuda et al.; 1st, first; 2nd, second

Back to article page